Brokerages Set Regeneron Pharmaceuticals Inc (REGN) Target Price at $394.19

Share on StockTwits

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned a consensus recommendation of “Hold” from the twenty-five research firms that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $399.93.

A number of research analysts recently issued reports on the stock. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday. Cowen restated a “hold” rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. TheStreet lowered shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Tuesday, November 13th. Argus restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 13th. Finally, ValuEngine upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 15th.

In other news, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, December 20th. The shares were sold at an average price of $358.97, for a total value of $663,376.56. Following the completion of the sale, the vice president now owns 9,871 shares in the company, valued at approximately $3,543,392.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.42% of the company’s stock.

Several large investors have recently added to or reduced their stakes in REGN. Capital International Investors bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $703,075,000. FMR LLC grew its position in Regeneron Pharmaceuticals by 17.0% in the 3rd quarter. FMR LLC now owns 5,016,501 shares of the biopharmaceutical company’s stock valued at $2,026,867,000 after purchasing an additional 728,104 shares during the period. Capital World Investors grew its position in Regeneron Pharmaceuticals by 5.3% in the 3rd quarter. Capital World Investors now owns 6,384,323 shares of the biopharmaceutical company’s stock valued at $2,579,522,000 after purchasing an additional 322,051 shares during the period. Alliancebernstein L.P. grew its position in Regeneron Pharmaceuticals by 35.8% in the 3rd quarter. Alliancebernstein L.P. now owns 1,023,594 shares of the biopharmaceutical company’s stock valued at $413,573,000 after purchasing an additional 269,696 shares during the period. Finally, Ffcm LLC grew its position in Regeneron Pharmaceuticals by 27,119.4% in the 3rd quarter. Ffcm LLC now owns 256,407 shares of the biopharmaceutical company’s stock valued at $11,599,000 after purchasing an additional 255,465 shares during the period. Institutional investors own 67.20% of the company’s stock.

NASDAQ REGN traded up $1.14 during trading hours on Friday, reaching $400.72. The company’s stock had a trading volume of 2,094 shares, compared to its average volume of 848,815. The firm has a market cap of $43.02 billion, a PE ratio of 29.88, a price-to-earnings-growth ratio of 1.71 and a beta of 1.14. Regeneron Pharmaceuticals has a 52 week low of $281.89 and a 52 week high of $416.49. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.94 by $0.93. The business had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the business earned $3.99 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 18.88 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Google Finance

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Perceptron, Inc.  Receives Consensus Rating of “Strong Buy” from Analysts
Perceptron, Inc. Receives Consensus Rating of “Strong Buy” from Analysts
$171.35 Million in Sales Expected for Ribbon Communications Inc  This Quarter
$171.35 Million in Sales Expected for Ribbon Communications Inc This Quarter
Achain Market Capitalization Reaches $5.77 Million
Achain Market Capitalization Reaches $5.77 Million
Vertcoin  Price Tops $0.24
Vertcoin Price Tops $0.24
Zacks: Brokerages Expect Automatic Data Processing  Will Post Earnings of $1.18 Per Share
Zacks: Brokerages Expect Automatic Data Processing Will Post Earnings of $1.18 Per Share
Dave & Buster’s Entertainment Inc  Receives Average Recommendation of “Buy” from Brokerages
Dave & Buster’s Entertainment Inc Receives Average Recommendation of “Buy” from Brokerages


Leave a Reply

© 2006-2019 Ticker Report